Scott D. Solomon

Research interests

Publications

• Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2407107

• Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

  New England Journal of Medicine · 2024 · 10.1056/nejmoa2409134

• SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)01429-5

• Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)02074-8

• Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2206286

• Potential Effects of Coronaviruses on the Cardiovascular System

  JAMA Cardiology · 2020 · 10.1001/jamacardio.2020.1286

• Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmsr2005760

• Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2020 · 10.1016/s0140-6736(20)31792-x

• Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1908655

• Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1911303

• How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

  European Heart Journal · 2019 · 10.1093/eurheartj/ehz641

• Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1716793

• Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1716153

• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1509225

• Spironolactone for Heart Failure with Preserved Ejection Fraction

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1313731

• Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1409077

• Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

  Circulation · 2014 · 10.1161/circulationaha.114.013748

• Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction

  Journal of the American College of Cardiology · 2013 · 10.1016/j.jacc.2013.09.052

• Strategies for Multivessel Revascularization in Patients with Diabetes

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1211585

• The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

  The Lancet · 2012 · 10.1016/s0140-6736(12)61227-6

• Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1208799

• Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography

  Journal of the American Society of Echocardiography · 2010 · https://doi.org/10.1016/j.echo.2010.05.010

• Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0906431

• A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

  New England Journal of Medicine · 2009 · 10.1056/nejmoa0907845

• Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

  European Heart Journal · 2008 · 10.1093/eurheartj/ehn153

• Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology

  Journal of the American Society of Echocardiography · 2005 · https://doi.org/10.1016/j.echo.2005.10.005

• Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

  New England Journal of Medicine · 2005 · 10.1056/nejmoa050405

• Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients

  Circulation · 2005 · 10.1161/circulationaha.105.561423

• Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

  New England Journal of Medicine · 2005 · 10.1056/nejmoa043938

• Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction

  New England Journal of Medicine · 2004 · 10.1056/nejmoa041365

• Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

  New England Journal of Medicine · 2003 · 10.1056/nejmoa032292

Current projects

No projects listed.